Drugs / BAH243
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06399107 | Aug 2024 → Nov 2025 overdue | sickle cell disease | Essen Biotech | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BAH243 | “BAH243 lentiviral vector (LVV) carrying the βA-T87Q-globin gene” NCT06399107 ↗ |
| Route | Intravenous | “administered by IV infusion” NCT06399107 ↗ |